AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance
May 25, 2021
By: Angus Liu
FiercePharma
Axinn partner Jeny Maier’s commentary was included in the FiercePharma article, "AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
LCA 2026 Renaissance Symposium XX
Speaking Engagement
Antitrust
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
Hot Topics in Health Care Antitrust
Podcast
Antitrust
Jimmy Attridge Repeats Recognition on Washingtonian Magazine’s 2026 Top Lawyers List
Awards & Recognitions
Antitrust
AIC General Counsel Day 2026
Speaking Engagement
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
Antitrust After the Midterms: Planning for a Blue Wave of Congressional Investigations
Axinn Viewpoints
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
